Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial

被引：0
|
作者：
Sharma, A. [1 ]
Inzucchi, S. E. [2 ]
Testani, J. [3 ]
Ofstad, A. P. [4 ]
Fitchett, D. [5 ]
Mattheus, M. [6 ]
Verma, S. [7 ]
Zannad, F. [8 ]
Wanner, C. [9 ]
Kraus, B. J. [10 ]
机构：
[1] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[2] Yale Univ, Sch Med, New Haven, CT USA
[3] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA
[4] Boehringer Ingelheim Norway KS, Asker, Norway
[5] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[7] Univ Toronto, St Michaels Hosp, Div Cardiac Surg, Toronto, ON, Canada
[8] Univ Lorraine, CHRU Nancy, Ctr Invest Clin Plurithemat 1433, INSERM 1116,FCRIN,INI,CRCT, Nancy, France
[9] Univ Hosp Wurzburg, Dept Internal Med 1, Wurzburg, Germany
[10] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [1] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffery
    Ofstad, Anne Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina
    INTERNIST, 2022, 63 (SUPPL 3): : 316 - 316
  • [2] Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffrey
    Ofstad, Anne-Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina J.
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S103 - S103
  • [3] Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
    Pellicori, Pierpaolo
    Fitchett, David
    Kosiborod, Mikhail N.
    Ofstad, Anne P.
    Seman, Leo
    Zinman, Bernard
    Zwiener, Isabella
    Wanner, Christoph
    George, Jyothis
    Inzucchi, Silvio E.
    Testani, Jeffrey M.
    Cleland, John G. F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (07) : 1085 - 1093
  • [4] EMPA-REG OUTCOME: A Milestone in the Treatment of the Diabetes mellitus Type 2?
    Schneider, C. A.
    Pfuetzner, A.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (06): : 405 - 407
  • [5] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
    Verma, Subodh
    Mazer, C. David
    Bhatt, Deepak L.
    Raj, Satish R.
    Yan, Andrew T.
    Verma, Atul
    Ferrannini, Ele
    Simons, Gudrun
    Lee, Jisoo
    Zinman, Bernard
    George, Jyothis T.
    Fitchett, David
    DIABETES CARE, 2019, 42 (03) : E42 - E44
  • [6] Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
    Sharma, Abhinav
    Ofstad, Anne Pernille
    Ahmad, Tariq
    Zinman, Bernard
    Zwiener, Isabella
    Fitchett, David H.
    Wanner, Christoph
    George, Jyothis T.
    Hantel, Stefan
    Desai, Nihar
    Mentz, Robert J.
    DIABETES, 2020, 69
  • [7] Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
    Cooper, Mark E.
    Inzucchi, Silvio E.
    Zinman, Bernard
    Hantel, Stefan
    von Eynatten, Maximilian
    Wanner, Christoph
    Koitka-Weber, Audrey
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 74 (05) : 713 - 715
  • [8] Use of loop diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial
    Pellicori, P.
    Fitchett, D.
    Kosiborod, M.
    Ofstad, A. P.
    Seman, L.
    Zinman, B.
    Zwiener, I.
    Wanner, C.
    George, J. T.
    Inzucchi, S. E.
    Testani, J.
    Cleland, J. G. F.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S444 - S445
  • [9] Effects of empagliflozin on cardiorenal outcomes in patients with type 2 diabetes and proteinuric diabetic kidney disease: insights from EMPA-REG OUTCOME
    Wanner, Christoph
    Zinman, Bernard
    von Eynatten, Maximilian
    Koitka-Weber, Audrey
    Zwiener, Isabella
    Hauske, Sibylle J.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [10] Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
    Verma, Subodh
    Mazer, C. David
    Al-Omran, Mohammed
    Inzucchi, Silvio E.
    Fitchett, David
    Hehnke, Uwe
    George, Jyothis T.
    Zinman, Bernard
    CIRCULATION, 2018, 137 (04) : 405 - 407
12345